Part 2/7:
AVXL has been a topic of intense interest recently, not least because of its close ties to surface similarities shared with the beleaguered Cassava Sciences. As of now, AVXL is priced around $9 a share with a market capitalization of $780 million. The company has attracted attention for its recent announcements, including the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its oral drug, blarcamesine.
Despite the excitement surrounding this development, the delivery of the company’s communications has raised some eyebrows. Observers criticized the grammar and clarity of AVXL's press releases, suggesting a lack of professionalism in its public communications—a concern that could undermine investor confidence.